

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

YAPC

RRID:CVCL_1794

Type: Cell Line

Proper Citation

RRID:CVCL_1794

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1794

Proper Citation: RRID:CVCL_1794

Description: Cell line YAPC is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic carcinoma

Defining Citation: [PMID:9533774](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: NCI RAS program mutant KRAS cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: YAPC

Cross References: CLO:CLO_0009711, EFO:EFO_0006778, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:342, BioSample:SAMN03472904, BioSample:SAMN03473329, BioSample:SAMN10988032, cancercellines:CVCL_1794, Cell_Model_Passport:SIDM00411, ChEMBL-Cells:ChEMBL3307253, ChEMBL-Targets:ChEMBL612815, Cosmic:909904, Cosmic:2046537, Cosmic:2434108, Cosmic-CLP:909904, DepMap:ACH-000332, DSMZ:ACC-382, DSMZCellDive:ACC-382, EGA:EGAS00001000610,

EGA:EGAS00001000978, GDSC:909904, GEO:GSM887742, GEO:GSM888837, GEO:GSM1670584, IARC_TP53:27267, IGRhCellID:YAPC, LiGeA:CCLE_222, LINCS_LDP:LCL-1792, PharmacoDB:YAPC_1679_2019, PRIDE:PXD030304, Progenetix:CVCL_1794, PubChem_Cell_line:CVCL_1794, Wikidata:Q54995282

ID: CVCL_1794

Record Creation Time: 20220427T221738+0000

Record Last Update: 20260904T020025+0000

Ratings and Alerts

No rating or validation information has been found for YAPC.

No alerts have been found for YAPC.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Benton A, et al. (2025) Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. Cancer cell, 43(7), 1365.

Girolimetti G, et al. (2025) Induced mitochondrial deficit by NDUFS3 transient silencing reduces RAB7 expression and causes lysosomal dysfunction in pancreatic cancer cells. Cell communication and signaling : CCS, 23(1), 224.

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. Nature communications, 16(1), 9996.

Girolimetti G, et al. (2024) Dysregulation of a Subset of Circulating and Vesicle-Associated miRNA in Pancreatic Cancer. Non-coding RNA, 10(3).

Girolimetti G, et al. (2024) Characterization of Chemoresistance in Pancreatic Cancer: A Look at MDR-1 Polymorphisms and Expression in Cancer Cells and Patients. International journal of molecular sciences, 25(15).

Paul MC, et al. (2023) Non-canonical functions of SNAIL drive context-specific cancer progression. Nature communications, 14(1), 1201.

Abt ER, et al. (2022) Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Cell

reports, 38(2), 110236.

Frank KJ, et al. (2022) Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. Cell reports. Medicine, 3(11), 100815.

Dorsch M, et al. (2021) Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. Cell reports, 37(8), 110056.

Neggers JE, et al. (2020) Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell reports, 33(11), 108493.

Wang Z, et al. (2020) SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Cancer cell, 37(6), 834.

Bi J, et al. (2019) Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell metabolism, 30(3), 525.

Litichevskiy L, et al. (2018) A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. Cell systems, 6(4), 424.